NCT07058090Not yet recruitingPhase 1
Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi
Source: ClinicalTrials.gov · Last updated 10 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
OBJECTIVE : To compare the outcome of treatment with silymarin or N-acetyl cysteine in patients taking anti-tuberculous drugs for tuberculosis at Tertiary Care Hospital, Karachi. SAMPLE SELECTION : Patients presenting with tuberculosis previously not on anti-tuberculous drugs, between 40-80 years of age, both genders will be included .Patients with history of alcohol use,Discontinuation of drug due to other adverse effects except hepatotoxicity ,Inadequate date of laboratory testing at baseline or 2 to 4 weeks after treatment initiation, Cases with human immunodeficiency virus (HIV) co-infection, viral hepatitis, or suspected mal absorption (e.g., gastrointestinal disease or diarrhea) ,Chronic liver disease, COPD, asthma, myocardial infarction, chronic kidney disease and stroke will be excluded
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 410 (estimated)
- First submitted
- 26 Jun 2025
- Start date
- Jul 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Liaquat National Hospital & Medical College
- Diseases
- Tuberculosis
- NCT number
- NCT07058090
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 410
- From Jul 2025 to the primary completion date, Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Discontinuation of drug due to other adverse effects except hepatotoxicity.
Other illness
- History of malignancy.
- Patients with history of seropositive, seronegative, connective tissue disorder or vasculitis, congestive cardiac failure.
- Patients with history of alcohol use.
- Cases with human immunodeficiency virus (HIV) co-infection, viral hepatitis, or suspected mal absorption (e.g., gastrointestinal disease or diarrhea).
- Chronic liver disease, COPD, asthma, myocardial infarction, chronic kidney disease and stroke.
Lab values
- Inadequate date of laboratory testing at baseline or 2 to 4 weeks after treatment initiation.
Who the study is looking for
- Patients presenting with tuberculosis and previously not on any anti-tuberculous drugs, between 40-80 years of age
- either gender.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.